Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Global pharmaceutical company having a surgical business concept incepted in Dubai
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
The joint venture will help both the parties to further develop the high-margin service business
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
